Porter D L, Levine B L, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J]. N Engl J Med, 2011, 365(8): 725-733. [2]Jensen M C, Riddell S R. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells[J]. Immunol Rev, 2014, 257(1): 127-144. [3]Kalos M, June C H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology[J]. Immunity, 2013, 39(1): 49-60. [4]Jena B, Dotti G, Cooper L J. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor[J]. Blood, 2010, 116(7): 1035-1044. [5]Gold P, Freedman S O. Specific carcinoembryonic antigens of the human digestive system[J]. J Exp Med, 1965, 122(3): 467-481. [6]Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues[J]. Semin Cancer Biol, 1999, 9(2): 67-81. [7]Gussow D, Seemann G. Humanization of monoclonal antibodies[J]. Methods Enzymol, 1991, 203:99-121. [8]Bruynck A, Seemann G, Bosslet K. Characterisation of a humanised bispecific monoclonal antibody for cancer therapy[J]. Br J Cancer, 1993, 67(3): 436-440. [9]Thorne S H, Negrin R S, Contag C H. Synergistic antitumor effects of immune cell-viral biotherapy[J]. Science, 2006, 311(5768): 1780-1784. [10]Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors[J]. Curr Opin Immunol, 2009, 21(2): 215-223. [11]Turtle C J. Chimeric antigen receptor modified T cell therapy for B cell malignancies[J]. Int J Hematol, 2014, 99(2): 132-140. [12]Kershaw M H, Westwood J A, Parker L L, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer[J]. Clin Cancer Res, 2006, 12(20 Pt 1): 6106-6115. [13]Lamers C H, Sleijfer S, Vulto A G, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience[J]. J Clin Oncol, 2006, 24(13): e20-e22. [14]Louis C U, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma[J]. Blood, 2011, 118(23): 6050-6056. [15]Kuroki M, Kuroki M, Shibaguchi H, et al. Strategies to endow cytotoxic T lymphocytes or natural killer cells with antibody activity against carcinoembryonic antigen[J]. Tumor Biol, 2004, 25(4): 208-216. [16]Klingemann H. Are natural killer cells superior CAR drivers?[J]. Oncoimmunology, 2014, 3:e28147. [17]Campana D, Schwarz H, Imai C. 4-1BB chimeric antigen receptors[J]. Cancer J, 2014, 20(2): 134-140. [18]Schonfeld K, Sahm C, Zhang C, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor[J]. Mol Ther, 2015, 23(2):330-338. [19]Lamers C H, Sleijfer S, van-Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity[J]. Mol Ther, 2013, 21(4): 904-912. [20]Grupp S A, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J]. N Engl J Med, 2013, 368(16): 1509-1518. [21]Marcus A, Eshhar Z. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer[J]. Expert Opin Biol Ther, 2014, 14(7): 947-954.
